Clostridioides difficile is a type of bacteria that often affects people who have been taking antibiotics, GST Micro LLC ...

The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut ...

Antibiotics can disrupt gut microbiota, leading to potential recurrences of Clostridioides difficile infections (CDI). New therapies like fecal microbiota transplantation (FMT) and monoclonal ...

When those bacteria die — for instance, as a result of antibiotic treatment for an unrelated infection — the large intestine becomes vulnerable, and this is often when C. difficile strikes.

Clostridioides difficile (C. diff) is a type of bacteria that may lead to severe diarrhea and colon inflammation. It’s often associated with taking antibiotics. According to the Centers for ...

Purpose The pharmacology, clinical efficacy, safety, dosage and administration, and place in therapy of fidaxomicin for the treatment of Clostridium difficile infection (CDI) are reviewed.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

However, if these people fall ill and are prescribed broad spectrum antibiotics C-diff can become a problem – that’s because the antibiotics wipe out the normal gut bacteria, allowing the ...

Most of the time, our bodies are able to keep C. diff at bay, but become less so as we age, and after a round of antibiotics, which can wipe out the “good” bacteria that keep C. diff in check.

with its lead antibiotic candidate, ibezapolstat, preparing to advance to international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). The Company today announced updates ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...